COMPANY

Oncotelic Therapeutics

HQ: Agoura Hills, CA source · oncotelic.com ↗ · West Coast

Keywords: RNA therapeutics small molecule infectious disease cancer infectious diseases oncology Pancreatic Ductal Adenocarcinoma Malignant Pleural Mesothelioma COVID-19 OT-101

Location: Agoura Hills, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $275K (Form D filed Dec 11, 2025). SEC Form D 0001493152-25-027270 (Dec 11, 2025)
Evidence (1 event)
- Dec 11, 2025 · SEC Form D 0001493152-25-027270
  Name of Issuer: Oncotelic Therapeutics, Inc.; CIK: 908259; Address: Agoura Hills, CA; Submission type: D; Filing date: 2025-12-11; Industry Group: Biotechnology; Date of First Sale: 2025-12-04; Types of Securities Offered: Equity, Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 12500000; Total Amount Sold: 275000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

2025-06 Trial start Phase 2: OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition source ↗
May 1, 2024 Trial start Phase 2/Phase 3: A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer source ↗
2021-04 Trial start Phase 2: A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects source ↗

Upcoming milestones

2028-12 (ESTIMATED) · Phase 2 · OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition · NCT05425576

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT06079346	A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer	Phase 2/Phase 3	Recruiting	May 1, 2024	Jun 1, 2026 (estimated)
NCT05425576	OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition	Phase 2	Not yet recruiting	2025-06	2028-12 (estimated)
NCT04801017	A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects	Phase 2	Unknown status (ClinicalTrials.gov)	2021-04	2021-08 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2025-12-11 Raise Private raise (SEC Form D): $275K sold of $12.5M offered; issuer “Oncotelic Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗